Most standard checkups miss the biomarkers that matter most for longevity. Here is every test worth ordering, why it matters, and where to get them without a doctor.
The standard annual physical in most Western countries is woefully inadequate from a longevity perspective. A typical panel might check your cholesterol (usually just total, LDL, HDL, and triglycerides), your complete blood count, and perhaps a basic metabolic panel. What it misses — the markers that most powerfully predict your trajectory toward or away from the major diseases of aging — is far more instructive than what it includes.
The reason for this inadequacy is partly historical (blood tests were expensive and limited decades ago when standard panels were established), partly cultural (medicine has been reactive rather than proactive), and partly economic (more testing costs more money in fee-for-service systems). But the cost of comprehensive blood testing has fallen dramatically, and the direct-to-consumer testing market now makes most longevity-relevant biomarkers accessible to anyone willing to seek them out.
This guide covers the comprehensive blood testing panel that longevity-focused physicians now consider essential, why each marker matters, and where to access these tests without waiting for a physician to order them.
ApoB (Apolipoprotein B): This is arguably the most important single cardiovascular biomarker and is almost never ordered in standard panels, despite being one of the most significant advances in cardiovascular risk assessment of the past two decades. Every atherogenic particle in your blood — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB molecule on its surface. ApoB therefore counts the total number of atherogenic particles rather than measuring the concentration of cholesterol they contain.
This distinction matters because you can have a low LDL-C (cholesterol concentration) while having high ApoB (many small, dense particles), which carries elevated cardiovascular risk. The particle count is more predictive than the cholesterol content. Peter Attia considers ApoB the primary lipid target and sets aggressive thresholds: below 60 mg/dL for those at elevated risk, below 80 mg/dL as a reasonable target for most people. Standard panels report LDL-C, which often misses the problem.